MedPath

Anger Control Training for Youth With Tourette Syndrome

Not Applicable
Completed
Conditions
Oppositional Defiant Disorder
Tourette Syndrome
ADHD
Chronic Tic Disorder
Registration Number
NCT00486551
Lead Sponsor
Yale University
Brief Summary

This is a clinical study of a cognitive-behavioral therapy known as anger control training in adolescents with Tourette Syndrome and explosive, disruptive behavior. ACT is compared to treatment as usual (TAU) in a randomized clinical trial.

Detailed Description

This is a randomized controlled study of a cognitive-behavioral, anger control training (ACT) in adolescents with Tourette Syndrome (TS) complicated by disruptive behavior. Disruptive behaviors in TS may take numerous forms including noncompliance, anger outbursts, and physical aggression. Anger outbursts in TS have been described as rage attacks or rage storms due to their high intensity and unpredictability in response to minimal provocation. Whether these behaviors are part of TS, related to comorbid conditions, or due to the burden of chronic illness is not clear. Nevertheless, these disruptive behaviors can result in significant functional impairment and often require clinical attention. The purpose of the ACT intervention is to improve the explosive and noncompliant behavior in adolescents with TS by enhancing affect regulation and social problem-solving skills. The treatment is based on anger control training which has been empirically supported for reducing aggressive behaviors and improving social functioning in aggressive youths. The primary outcome measures include the parent-rated Oppositional Defiant Scale and the Clinicians Global Improvement Score assessed by a clinician blind to treatment assignment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26
Inclusion Criteria
  1. Boys and girls, 11 to 16 years of age.
  2. Diagnosis of Tourette syndrome (TS) or chronic tic disorder (CTD).
  3. Significant level of disruptive behavior
Exclusion Criteria
  1. Current diagnosis of Severe Major Depression, Bipolar Disorder, Pervasive Developmental Disorder, or Psychotic Disorder.
  2. Significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, seizure disorder that may require more pressing treatment.
  3. Initiation or discontinuation of a psychotropic medication treatment within six weeks of enrollment in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Parent rated disruptive behaviorthree months
CGI-I assigned by clinician unaware of treatment assignmentthree months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Yale University School of Medicine, Child Study Center

🇺🇸

New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath